If you're an employer funding retiree drug benefits or offering Medicare Advantage, sit down. I'll show you a problem that's right in front of you, one that's quietly costing you millions while your retirees get sicker and poorer.
I've spent nearly twenty years inside the employee benefits system. I've watched employers pour billions into wellness programs, pharmacy carve-outs, and health plan redesigns, all while a parallel system silently undermines everything they're trying to do. That system is Medicare Part D.
The Incentive That Works Against You
Almost nobody in benefits will say this out loud: Medicare Part D was never designed to make anyone healthier or wealthier. It was designed to pay for prescriptions and nothing else.
Think about what a truly aligned system looks like. When an employee takes a preventive scan, completes a health screening, or sticks with their medication, they get rewarded. Real dollars. Store dollars. Retirement contributions. That's the Health-to-Wealth model. Prevention pays.
Now look at Medicare Part D. An enrollee who manages their blood pressure through diet and exercise? The system doesn't care. The entire revenue model depends on them not doing that. Every prescription filled generates profit. Every avoided prescription is a missed opportunity for the system.
That's structural design.
Where Your Retiree Drug Dollars Actually Go
If you've been frustrated by PBM opacity in your commercial plans, that same black box has fully migrated to Medicare.
MedPAC's June 2023 report to Congress found that manufacturer rebates and other price concessions in Part D grew from $8.6 billion in 2010 to $62.7 billion in 2021, rising from 11 percent to 29 percent of gross drug spending. Those rebates don't lower the price at the pharmacy counter. They reduce premiums across the plan, and they flow through a negotiation and reporting chain that plan sponsors and employers often can't see into clearly.
Those dollars steer formularies toward high-priced, high-rebate drugs rather than lower-cost options, and the point-of-sale price a beneficiary faces can be higher as a result. The opacity means an employer funding retiree coverage can't audit where the money actually lands.
What the Inflation Reduction Act Changed, and What It Didn't
The Inflation Reduction Act redesigned Part D starting in 2025. It capped annual out-of-pocket drug costs at $2,000, eliminated the coverage gap, and replaced the Coverage Gap Discount Program with a Manufacturer Discount Program. Medicare price negotiation for selected drugs began in 2026.
Those changes lower what a retiree pays at the counter and what the government pays for certain drugs. They don't change the core design. Nothing in Part D rewards a retiree for the preventive actions that keep them off medication, and the rebate chain between manufacturer, PBM, and plan remains opaque. For an employer funding retiree coverage, the redesign trimmed some numbers without fixing the incentive.
The Cliff at Age 65
This is the part that keeps me up at night. An employee spends their entire career in a Health-to-Wealth system. They scan. They earn. They build a pension. They watch their store dollars grow. They get healthier every year because the system rewards them for it.
Then they turn 65.
Everything they built disappears. No more store dollars. No more pension boosts. No more connection between their health choices and their financial future. They fall off a cliff into a system that wants them to take more pills, not fewer. WellthCare, the first Health-to-Wealth Benefit System, keeps that connection alive across the lifespan, so preventive care and store rewards don't stop at 65.
It's bad design and a betrayal of everything we're trying to accomplish in employer benefits.
What the Next Generation of Retiree Benefits Looks Like
I'm convinced the solution is coming. It looks like this:
- Rewards don't stop at 65. Preventive health actions should continue earning store dollars and retirement contributions after Medicare enrollment. The system follows the person, not their age.
- Transparent pharmacy pricing replaces the black box. The same 20-40% savings that Health-to-Wealth pharmacy models deliver for active employees should extend to retirees. No spread pricing. No hidden rebates.
- Personalized care prompts continue across the lifespan. The AI concierge that reminds an employee to take their medications shouldn't stop because they turn 65. Adherence support is more valuable for an aging population.
- Real data reduces total cost. When you can measure whether people are actually taking their medications and reward them for it, you reduce hospitalizations, complications, and overall spend.
The Bottom Line
The next big move in benefits is a continuous Health-to-Wealth system that doesn't stop at 65.
First movers will cut retiree drug costs. Improve outcomes for aging workers. Build a market position nobody can touch.
Medicare Part D is broken for a reason that goes deeper than pricing or regulations. It was never designed to build either health or wealth.
The companies that fix that will define the next decade of employee benefits.